Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biota Scientific Management Pty Ltd
Subjects with a previous diagnosis of asthma will be pre screened within 90 days prior to enrolment. If a subject develops symptoms of human rhinovirus (HRV) infection they will visit the site for assessment. Symptomatic subjects meeting all eligibility criteria will be invited to enroll.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female subjects aged 18-70 years
Diagnosis of asthma consistent with Global Initiative for Asthma (GINA) steps 1 to 3
Presumptive human rhinovirus infection
You may not be if
Current severe asthma exacerbation
Severe asthma, GINA steps 4 or higher
Uncontrolled or clinically significant medical condition, disease or event which could impact subject safety and/or study evaluations and/or compliance to the protocol
Current smoker, ex-smoker of \<1 year, or history of smoking \>/=10 pack years.
Clareo Health | A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
